Hitherto, elevated serum GGT has been studied extensively as an unfavorable prognostic biomarker in patients with liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, on which dozens of clinical studies have been conducted. Here, GGT1 is linked to liver cancer.